Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

G. Cazzaniga, P. De Lorenzo, J. Alten, S. Röttgers, J. Hancock, V. Saha, A. Castor, HO. Madsen, V. Gandemer, H. Cavé, V. Leoni, R. Köhler, GM. Ferrari, K. Bleckmann, R. Pieters, V. van der Velden, J. Stary, J. Zuna, G. Escherich, UZ. Stadt, M....

. 2018 ; 103 (1) : 107-115. [pub] 20171027

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035552

Grantová podpora
14840 Cancer Research UK - United Kingdom
NV16-30186A MZ0 CEP - Centrální evidence projektů

The prognostic value of minimal residual disease (MRD) in Philadelphia-chromosome-positive (Ph+) childhood acute lymphoblastic leukemia (ALL) treated with tyrosine kinase inhibitors is not fully established. We detected MRD by real-time quantitative polymerase chain reaction (RQ-PCR) of rearranged immunoglobulin/T-cell receptor genes (IG/TR) and/or BCR/ABL1 fusion transcript to investigate its predictive value in patients receiving Berlin-Frankfurt-Münster (BFM) high-risk (HR) therapy and post-induction intermittent imatinib (the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia (EsPhALL) study). MRD was monitored after induction (time point (TP)1), consolidation Phase IB (TP2), HR Blocks, reinductions, and at the end of therapy. MRD negativity progressively increased over time, both by IG/TR and BCR/ABL1. Of 90 patients with IG/TR MRD at TP1, nine were negative and none relapsed, while 11 with MRD<5×10-4 and 70 with MRD≥5×10-4 had a comparable 5-year cumulative incidence of relapse of 36.4 (15.4) and 35.2 (5.9), respectively. Patients who achieved MRD negativity at TP2 had a low relapse risk (5-yr cumulative incidence of relapse (CIR)=14.3[9.8]), whereas those who attained MRD negativity at a later date showed higher CIR, comparable to patients with positive MRD at any level. BCR/ABL1 MRD negative patients at TP1 had a relapse risk similar to those who were IG/TR MRD negative (1/8 relapses). The overall concordance between the two methods is 69%, with significantly higher positivity by BCR/ABL1. In conclusion, MRD monitoring by both methods may be functional not only for measuring response but also for guiding biological studies aimed at investigating causes for discrepancies, although from our data IG/TR MRD monitoring appears to be more reliable. Early MRD negativity is highly predictive of favorable outcome. The earlier MRD negativity is achieved, the better the prognosis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035552
003      
CZ-PrNML
005      
20191011123250.0
007      
ta
008      
191007s2018 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2017.176917 $2 doi
035    __
$a (PubMed)29079599
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Cazzaniga, Giovanni $u Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Monza, Italy gianni.cazzaniga@hsgerardo.org.
245    10
$a Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies / $c G. Cazzaniga, P. De Lorenzo, J. Alten, S. Röttgers, J. Hancock, V. Saha, A. Castor, HO. Madsen, V. Gandemer, H. Cavé, V. Leoni, R. Köhler, GM. Ferrari, K. Bleckmann, R. Pieters, V. van der Velden, J. Stary, J. Zuna, G. Escherich, UZ. Stadt, M. Aricò, V. Conter, M. Schrappe, MG. Valsecchi, A. Biondi,
520    9_
$a The prognostic value of minimal residual disease (MRD) in Philadelphia-chromosome-positive (Ph+) childhood acute lymphoblastic leukemia (ALL) treated with tyrosine kinase inhibitors is not fully established. We detected MRD by real-time quantitative polymerase chain reaction (RQ-PCR) of rearranged immunoglobulin/T-cell receptor genes (IG/TR) and/or BCR/ABL1 fusion transcript to investigate its predictive value in patients receiving Berlin-Frankfurt-Münster (BFM) high-risk (HR) therapy and post-induction intermittent imatinib (the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia (EsPhALL) study). MRD was monitored after induction (time point (TP)1), consolidation Phase IB (TP2), HR Blocks, reinductions, and at the end of therapy. MRD negativity progressively increased over time, both by IG/TR and BCR/ABL1. Of 90 patients with IG/TR MRD at TP1, nine were negative and none relapsed, while 11 with MRD<5×10-4 and 70 with MRD≥5×10-4 had a comparable 5-year cumulative incidence of relapse of 36.4 (15.4) and 35.2 (5.9), respectively. Patients who achieved MRD negativity at TP2 had a low relapse risk (5-yr cumulative incidence of relapse (CIR)=14.3[9.8]), whereas those who attained MRD negativity at a later date showed higher CIR, comparable to patients with positive MRD at any level. BCR/ABL1 MRD negative patients at TP1 had a relapse risk similar to those who were IG/TR MRD negative (1/8 relapses). The overall concordance between the two methods is 69%, with significantly higher positivity by BCR/ABL1. In conclusion, MRD monitoring by both methods may be functional not only for measuring response but also for guiding biological studies aimed at investigating causes for discrepancies, although from our data IG/TR MRD monitoring appears to be more reliable. Early MRD negativity is highly predictive of favorable outcome. The earlier MRD negativity is achieved, the better the prognosis.
650    _2
$a nádorové biomarkery $7 D014408
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a bcr-abl fúzní proteiny $x genetika $7 D016044
650    _2
$a lidé $7 D006801
650    _2
$a imatinib mesylát $x terapeutické užití $7 D000068877
650    _2
$a imunoglobuliny $x genetika $7 D007136
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a reziduální nádor $x diagnóza $x genetika $7 D018365
650    _2
$a akutní lymfatická leukemie $x diagnóza $x farmakoterapie $x genetika $x mortalita $7 D054198
650    _2
$a prognóza $7 D011379
650    _2
$a receptory antigenů T-buněk $x genetika $7 D011948
650    _2
$a recidiva $7 D012008
650    _2
$a analýza přežití $7 D016019
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a De Lorenzo, Paola $u Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Monza, Italy. European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia (EsPhALL) Trial Data Center, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
700    1_
$a Alten, Julia $u Berlin-Frankfurt-Münster Group Germany (BFM-G), Germany and Switzerland.
700    1_
$a Röttgers, Silja $u Berlin-Frankfurt-Münster Group Germany (BFM-G), Germany and Switzerland.
700    1_
$a Hancock, Jeremy $u Children's Cancer and Leukaemia Group (CCLG), UK.
700    1_
$a Saha, Vaskar $u Children's Cancer and Leukaemia Group (CCLG), UK.
700    1_
$a Castor, Anders $u Nordic Society of Paediatric Haematology and Oncology (NOPHO), Sweden, Denmark, Norway, Finland and Iceland.
700    1_
$a Madsen, Hans O $u Nordic Society of Paediatric Haematology and Oncology (NOPHO), Sweden, Denmark, Norway, Finland and Iceland.
700    1_
$a Gandemer, Virginie $u French Acute Lymphoblastic Leukemia Study Groups (French Acute Lymphoblastic Leukemia Study Group, FRALLE and European Organisation for Research and Treatment of Cancer, EORTC), Italy.
700    1_
$a Cavé, Hélène $u French Acute Lymphoblastic Leukemia Study Groups (French Acute Lymphoblastic Leukemia Study Group, FRALLE and European Organisation for Research and Treatment of Cancer, EORTC), Italy.
700    1_
$a Leoni, Veronica $u Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.
700    1_
$a Köhler, Rolf $u Berlin-Frankfurt-Münster Group Germany (BFM-G), Germany and Switzerland.
700    1_
$a Ferrari, Giulia M $u Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.
700    1_
$a Bleckmann, Kirsten $u Berlin-Frankfurt-Münster Group Germany (BFM-G), Germany and Switzerland.
700    1_
$a Pieters, Rob $u Dutch Childhood Oncology Group (DCOG), the Netherlands.
700    1_
$a van der Velden, Vincent $u Dutch Childhood Oncology Group (DCOG), the Netherlands.
700    1_
$a Stary, Jan $u Czech Pediatric Hematology Working Group (CPH), Czech Republic.
700    1_
$a Zuna, Jan $u Czech Pediatric Hematology Working Group (CPH), Czech Republic.
700    1_
$a Escherich, Gabriele $u Cooperative study group for treatment of ALL (COALL), Germany.
700    1_
$a Stadt, Udo Zur $u Cooperative study group for treatment of ALL (COALL), Germany.
700    1_
$a Aricò, Maurizio $u Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Azienda Sanitaria Provinciale, Ragusa, Italy.
700    1_
$a Conter, Valentino $u Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.
700    1_
$a Schrappe, Martin $u Berlin-Frankfurt-Münster Group Germany (BFM-G), Germany and Switzerland.
700    1_
$a Valsecchi, Maria Grazia $u European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia (EsPhALL) Trial Data Center, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
700    1_
$a Biondi, Andrea $u Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Monza, Italy. Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 103, č. 1 (2018), s. 107-115
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29079599 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191011123710 $b ABA008
999    __
$a ok $b bmc $g 1452212 $s 1074102
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 103 $c 1 $d 107-115 $e 20171027 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
GRA    __
$a 14840 $p Cancer Research UK $2 United Kingdom
GRA    __
$a NV16-30186A $p MZ0
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace